Cogent Biosciences (COGT) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Cogent Biosciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $384M of COGT stock on the open market.
Get emailed when insiders cluster-buy stocks like COGT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
COGT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.7M | 2 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $370M | 2 |
| Q4 2025 | — | 0 | $12.2M | 4 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Cogent Biosciences, Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $384M. 2 of 8 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 31SEC | Arlene MorrisDirector | Sell Plan | 42,3493,161 held (−93%) | $37.09 | $1.6M | -16.4% | — |
| Aug 31SEC | Arlene MorrisDirector | Sell Plan | 3,161 | $37.54 | $119K | -17.4% | — |
| Mar 31SEC | Fairmount Funds Management LlcDirector | Sell | 7,000,0005,503,418 held (−56%) | $34.66 | $243M | -10.6% | — |
| Jan 22SEC | Fairmount Funds Management LlcDirector | Sell | 3,500,0005,503,418 held (−39%) | $36.40 | $127M | -14.8% | — |
| Dec 30SEC | John Edward RobinsonChief Scientific Officer | Sell | 90,000140,002 held (−39%) | $38.74 | $3.5M | -20.0% | — |
| Dec 30SEC | Jessica SachsChief Medical Officer | Sell | 82,642133,938 held (−38%) | $38.70 | $3.2M | -19.9% | — |
| Dec 30SEC | John L. GreenCFO | Sell | 77,000131,834 held (−37%) | $38.68 | $3.0M | -19.9% | — |
| Dec 30SEC | Evan KearnsGeneral Counsel | Sell | 65,000109,398 held (−37%) | $38.70 | $2.5M | -19.9% | — |
Insiders at Cogent Biosciences, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Fairmount Funds Management LlcDirector | — | $370M | Mar 31, 2026 | — |
| John Edward RobinsonChief Scientific Officer | — | $3.5M | Dec 30, 2025 | — |
| Jessica SachsChief Medical Officer | — | $3.2M | Dec 30, 2025 | — |
| John L. GreenCFO | — | $3.0M | Dec 30, 2025 | — |
| Evan KearnsGeneral Counsel | — | $2.5M | Dec 30, 2025 | — |
| Arlene MorrisDirector | — | $1.7M | Aug 31, 2026 | — |
COGT stock: common questions
Are Cogent Biosciences, Inc. insiders buying COGT stock?
In the past 12 months, 0 insiders reported open-market purchases of COGT worth $0.
Are Cogent Biosciences, Inc. insiders selling COGT stock?
6 insiders reported sales worth $384M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is COGT's 52-week range?
Over the past year COGT has traded between $14.13 and $42.84. It last closed at $31.00 on Oct 9, 2026.